Synergistic promotion of transient transgene expression in CHO cells by PDI/XBP-1s co-transfection and mild hypothermia
In conclusion, the combination of PDI/XBP-1s overexpression and culture temperature optimization can achieve higher transient expression of recombinant protein, which provides a synergetic strategy to improve transient production of recombinant protein in CHO cells.PMID:38416261 | DOI:10.1007/s00449-024-02987-5 (Source: Bioprocess and Biosystems Engineering)
Source: Bioprocess and Biosystems Engineering - February 28, 2024 Category: Biomedical Engineering Authors: Xi Zhang Yaokun Wang Dandan Yi Chi Zhang Binhuan Ning Yushun Fu Yanlong Jia Tianyun Wang Xiaoyin Wang Source Type: research
Synergistic promotion of transient transgene expression in CHO cells by PDI/XBP-1s co-transfection and mild hypothermia
In conclusion, the combination of PDI/XBP-1s overexpression and culture temperature optimization can achieve higher transient expression of recombinant protein, which provides a synergetic strategy to improve transient production of recombinant protein in CHO cells.PMID:38416261 | DOI:10.1007/s00449-024-02987-5 (Source: Bioprocess and Biosystems Engineering)
Source: Bioprocess and Biosystems Engineering - February 28, 2024 Category: Biomedical Engineering Authors: Xi Zhang Yaokun Wang Dandan Yi Chi Zhang Binhuan Ning Yushun Fu Yanlong Jia Tianyun Wang Xiaoyin Wang Source Type: research
Drug Retention Time of Immunosuppressive Therapy in Behcet's Uveitis
CONCLUSION: Adalimumab's drug retention time was found to be similar to and possibly better than cDMARDs in patients with BU, who often suffer from vision-threatening disease at first presentation.PMID:38412375 | DOI:10.1080/09273948.2024.2315205 (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - February 27, 2024 Category: Allergy & Immunology Authors: Donald Tran Sophie Rogers Lyndell L Lim Source Type: research
GSE247146 Blood gene expression biomarkers of response to anti-TNF drugs in pediatric patients before initiation of treatment
Conclusions: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - February 26, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
A call for guidance on the treatment of patients taking disease-modifying anti-rheumatic drugs (DMARDs)
Disease-modifying anti-rheumatic drug (DMARD) use in patients presenting to oral and maxillofacial departments should be duly noted. DMARDs lead to immunosuppression and have the potential to suppress anti-tumour immunity.1 DMARD is an encompassing term for both conventional DMARDs (for example, methotrexate, hydroxychloroquine, sulfasalazine, and azathioprine), biologic DMARDs (for example, adalimumab and rituximab), and targeted synthetic DMARDs (for example, filgotinib). DMARDs are increasingly used for cancer and autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn ’s disease. (Source: The British J...
Source: The British Journal of Oral and Maxillofacial Surgery - February 26, 2024 Category: ENT & OMF Authors: Kirsty Skye Dickson, Alasdair Regan, Callum Wemyss, Martin Paley, Arshad Siddiqui Tags: Letter to the Editor Source Type: research
Long ‐term efficacy, safety, and cumulative retention rate of antitumor necrosis factor‐alpha treatment for patients with Behcet's uveitis: A systematic review and meta‐analysis
ConclusionsAnti-TNF- α therapy represents an effective treatment for BU patients with favorable safety profile and high drug retention rate and a potential advantage of adalimumab over infliximab in terms of ocular inflammation remission, drug retention, and the incidence of severe infusion or injection reactions. (Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - February 25, 2024 Category: Rheumatology Authors: Xin Guan,
Zerui Zhao,
Miaomiao Xin,
Guangtao Xia,
Qingrui Yang,
Min Fu Tags: ORIGINAL ARTICLE Source Type: research
Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment
CONCLUSIONS: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs.PMID:38401525 | DOI:10.1016/j.biopha.2024.116299 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 24, 2024 Category: Drugs & Pharmacology Authors: Sara Salvador-Mart ín Gianluca Rubbini Perceval Vellosillo Paula Zapata-Cobo Marta Velasco Laura M Palomino Susana Clemente Oscar Segarra Ana Moreno- Álvarez Ana Fern ández-Lorenzo Bego ña Pérez-Moneo Montserrat Montraveta Cesar S ánchez Mar Tol ín Source Type: research
Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment
CONCLUSIONS: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs.PMID:38401525 | DOI:10.1016/j.biopha.2024.116299 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 24, 2024 Category: Drugs & Pharmacology Authors: Sara Salvador-Mart ín Gianluca Rubbini Perceval Vellosillo Paula Zapata-Cobo Marta Velasco Laura M Palomino Susana Clemente Oscar Segarra Ana Moreno- Álvarez Ana Fern ández-Lorenzo Bego ña Pérez-Moneo Montserrat Montraveta Cesar S ánchez Mar Tol ín Source Type: research
Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment
CONCLUSIONS: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs.PMID:38401525 | DOI:10.1016/j.biopha.2024.116299 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 24, 2024 Category: Drugs & Pharmacology Authors: Sara Salvador-Mart ín Gianluca Rubbini Perceval Vellosillo Paula Zapata-Cobo Marta Velasco Laura M Palomino Susana Clemente Oscar Segarra Ana Moreno- Álvarez Ana Fern ández-Lorenzo Bego ña Pérez-Moneo Montserrat Montraveta Cesar S ánchez Mar Tol ín Source Type: research
Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report
We report an Asian patient with a 16-year-history of GPP and ACH with marked pustulosis on the nail bed and onychodystrophy. He received conventional systemic regimen acitretin, cyclosporine and biologics adalimumab and secukinumab, but experienced relapse for skin lesions and refractory for nail lesions. He was then treated with a single dose of spesolimab in combination with secukinumab, which resulted in skin clearance and nearly complete resolution of nail lesions over a 32-week period. Our observation suggests that spesolimab should be considered for the treatment of ACH, especially in the patients with intractable na...
Source: Frontiers in Immunology - February 23, 2024 Category: Allergy & Immunology Source Type: research
Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto
(Source: Clinical Rheumatology)
Source: Clinical Rheumatology - February 22, 2024 Category: Rheumatology Source Type: research
Effect of adalimumab on choroidal thickness and choroidal vascularity index in eyes with non-infectious uveitis using enhanced-depth imaging optical coherence tomography
Eye, Published online: 20 February 2024; doi:10.1038/s41433-024-02975-9Effect of adalimumab on choroidal thickness and choroidal vascularity index in eyes with non-infectious uveitis using enhanced-depth imaging optical coherence tomography (Source: Eye)
Source: Eye - February 20, 2024 Category: Opthalmology Authors: Cem Evereklioglu Elif Er Arslantas Hidayet Sener Zeynep Akkul Kamran Gahramanov Duygu Gulmez Sevim Osman Ahmet Polat Fatih Horozoglu Source Type: research
Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto
(Source: Clinical Rheumatology)
Source: Clinical Rheumatology - February 19, 2024 Category: Rheumatology Source Type: research
Infliximab for maintenance of medically-induced remission in Crohn's disease
CONCLUSIONS: Infliximab is probably more effective in preventing clinical relapse than placebo (moderate-certainty evidence). Infliximab in combination with purine analogues is probably more effective in preventing clinical and endoscopic relapse than purine analogues alone (moderate-certainty evidence). No conclusions can be drawn regarding prevention of loss of clinical response, occurrence of withdrawals due to adverse events, or total adverse events due to very low-certainty evidence for both of these comparisons. There may be little or no difference in prevention of clinical relapse, withdrawal due to adverse events o...
Source: Cochrane Database of Systematic Reviews - February 19, 2024 Category: General Medicine Authors: Morris Gordon Vassiliki Sinopoulou Anthony K Akobeng Arni Sarian Gordon William Moran Source Type: research
Bovine ultralong CDR-H3 derived knob paratopes elicit potent TNF- α neutralization and enable the generation of novel adalimumab-based antibody architectures with augmented features
Biol Chem. 2024 Feb 20. doi: 10.1515/hsz-2023-0370. Online ahead of print.ABSTRACTIn this work we have generated cattle-derived chimeric ultralong CDR-H3 antibodies targeting tumor necrosis factor α (TNF-α) via immunization and yeast surface display. We identified one particular ultralong CDR-H3 paratope that potently neutralized TNF-α. Interestingly, grafting of the knob architecture onto a peripheral loop of the CH3 domain of the Fc part of an IgG1 resulted in the generation of a TNF-α neutralizing Fc (Fcknob) that did not show any potency loss compared with the parental chimeric IgG format. Eventually, grafting this...
Source: Biological Chemistry - February 19, 2024 Category: Chemistry Authors: Paul Arras Jasmin Zimmermann Britta Lipinski Bernhard Valldorf Andreas Evers Desislava Elter Simon Krah Achim Doerner Enrico Guarnera Vanessa Siegmund Harald Kolmar Lukas Pekar Stefan Zielonka Source Type: research
